SEC Form 4 · accession 0001104659-26-077427
Apogee Therapeutics, Inc. · APGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carl Dambkowski
Officer — Chief Medical Officer
Period of report
Jun 22, 2026
Accepted (ET)
Jun 24, 2026 · 8:01 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001974640
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 22, 2026 | S | 26,400 | $132.60 | D | 179,248 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.
- F2The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.550 to $132.645, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.